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1. Introduction 
Comprehensive profiling of genome and transcriptome has identified myriads of 
alternations at the level of gene and gene expression, which drive malignant development 
and progression in context of oncology. As a result, qualitative or quantitative changes of 
protein expression pattern will inevitably ensue during multi-stage of carcinogenesis. In this 
sense, the proteome is a functional translation of the genome and is the actual manipulator 
of cellular behavior. Therefore, proteomic profiling of cellular protein constituents should 
generate the most relevant marker of the functional state of a cell. On the other hand, lack of 
correlation between mRNA and protein expression have been documented for a variety of 
genes. Unlike the genome which is static in certain sense, the proteome of a cell is dynamic 
and changes over time in terms of protein pattern, protein interactions and modifications 
triggered by external or internal signals[Kolch et al., 2004; Kolch et al., 2005]. Only dynamic 
information flow through protein circuitry reflects the course of a disease and allows us to 
track the pathogenetic mechanisms as well as treatment response[Kolch et al., 2005]. 
Furthermore, examining DNA sequences and measuring mRNA expression do not specify 
splicing, post-translational modifications, cleavages, protein subcellular localization and 
complex formations[Banks et al., 2000; Chambers et al., 2000]. There exists a huge 
information gulf between RNA transcription and protein expression. Proteome represents a 
much richer source for the functional description of diseases and the biomarker discovery 
implicated in cancer. Moreover, most of diagnostic assays currently applied in clinical 
practice are protein-based immunological methods, which are well adapted to 
standardization and clinical implementation. Proteomic profiling during disease formation 
and evolution not only provides an integrated understanding of pathogenesis in context of 
genome and proteome but also holds greater promise to identify the biomarkers of 
diagnosis and therapeutic targets for diseases such as cancer.  
1.1 Epidemiology and etiology of ESCC 
Accounting for more than 400,000 deaths per year, esophageal cancer (EC) ranks as the sixth 
most common cause of cancer-related mortality worldwide[Parkin et al., 2005]. Moreover, 
about half of world’s EC cases newly diagnosed each year occurred in China[Holmes & 
Vaughan, 2007]. Histologically, esophageal squamous cell carcinoma (ESCC) and esophageal  
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adenocarcinoma (EAC) contribute to more than 90% of EC[Daly et al., 2000]. In China, ESCC is 
the predominant histological subtype and account for nearly 90% of all EC[Li et al., 2011]. In 
developed countries, in contrast, EAC has been increasingly more frequent over the past two 
decades and has now surpassed the previously more predominant ESCC[Brown et al., 2008; 
Trivers et al., 2008]. The incidence of ESCC is characterized by its striking geographical 
distribution across the world. In the extremely high incidence areas, e.g. northern China, the 
incidence of EC exceeds 100/100 000/year, while the incidence is less than 5/100 000/year in 
Europe and the USA[Cheng & Day, 1996]. Heavy smoking and alcohol consumption are 
associated with increased risk of ESCC in developed countries[Brown et al., 2008; Messmann, 
2001; Morita et al., 2010], but not major contributing factors in the pathogenesis of ESCC in 
China, where major risk factors include nutritional deficiency, consumption of pickled 
vegetables, dietary contamination with nitrosamine or mycotoxin, and low socioeconomic 
status[Kamangar et al., 2009; Yang et al., 1984]. In light of the poor nutrition status in Linxian, 
one of the highest incidence areas for ESCC in the world, two large nutrition intervention 
studies implemented in the late 1980s reported that the combination of selenium/vitamin E/ǃ-
carotene significantly reduced total mortality, total cancer mortality and stomach cancer 
incidence[Blot et al., 1993; Li et al., 1993]. High baseline serum selenium concentrations 
showed strong protective effects on ESCC and stomach cancer in prospective studies[Mark et 
al., 2000]. Recently, opposing trends in incidence of EAC and ESCC, i.e. decrease of ESCC 
incidence and reciprocal increase of EAC incidence has been observed not only worldwide but 
also in high risk areas in China, pointing to the roles of economic level and lifestyle factors in 
EC pattern change[Devesa et al., 1998; Fan et al., 2008; Hongo et al., 2009]. In addition, familial 
aggregation of ESCC has been reported in high-risk areas for ESCC[Chang-Claude et al., 1997]. 
Taken together, these facts indicate that both genetic susceptibility and environmental risk 
factors contribute to the etiology of ESCC.  
1.2 Current situation of clinical management of ESCC 
Early detection of ESCC is formidable and the majority of ESCC patients have advanced 
metastatic disease at initial diagnosis. Therefore, 40-60% ESCC patients are inappropriate for 
curative resection, which remains the primary treatment of ESCC as it provides sustained 
palliation of dysphagia and the best chance of cure[Hagymasi & Tulassay, 2007; Triboulet et 
al., 2001]. Nonetheless, more than 50% ESCC develop recurrence within 2-3 years after 
surgery[Dresner & Griffin, 2000; Hulscher et al., 2000; Nakagawa et al., 2004]. Moreover, the 
overall 5-year survival rate is < 10% despite significant improvements in surgical techniques 
and adjuvant chemoradiation[Lightdale, 1999]. In contrast, the 5-year survival rate for EC 
patients at early stages could be as high as 90%[Hu et al., 2001]. Long-term survival 
correlates with stages of EC, as evidenced by 40-62% of 5-year survival rate for stage I and 
IIA contrasting with 18-25% for stage IIB and III of EC[Iizuka et al., 1989]. This suggests that 
the reasons for this disappointingly low survival rate include ineffective screening tools for 
high-risk population, cancer detection at an advanced stage, high-risk for recurrence, lack of 
targets for treatment, unreliable noninvasive tools to monitor complete response to 
chemoradiotherapy and so on. Clearly, identification of effective biomarkers for early 
detection, monitoring tumor progression and potential therapeutic targets offer the best 
chances to lower the morbidity and mortality of ESCC.  
1.3 Molecular biology studies of ESCC and its contribution to clinical management 
Extensive molecular biology studies of ESCC have identified a wealth of dysregulated 
molecular events involved in esophageal carcinogenesis, which cover a broad range of genes 
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with diverse functions, such as vulnerable genes to chemicals, tumor-related genes, tumor 
suppressor genes, metastasis genes, apoptosis gene, proliferation genes, etc[Enzinger & 
Mayer, 2003; Greenawalt et al., 2007; Kwong, 2005; Lin et al., 2009]. Moreover, epigenetic 
alterations, chromosomal changes and transcriptional changes have also been found to play 
crucial roles in the pathogenesis of ESCC[Abnet et al., 2010; Greenawalt et al., 2007; Wang et 
al., 2010]. Although these findings improve our general understanding about the molecular 
biology of ESCC, the appropriate biomarkers for high-risk population screening, for clinical 
diagnosis and prognosis, for evaluation of treatment efficiency have not been identified yet. 
Therefore, it is imperative to search more effective biomarkers for such purposes. 
2. ESCC analysis by proteomics 
2.1 Advantages of proteomics compared with genomics 
The completion of human genome sequence did not ensure panacea solutions to all 
problems related to biological deregulation. In fact, human proteome is far more complex 
and dynamic than genome sequence. It is estimated that the human genome contains about 
32 000 protein coding genes, which code for 100 000 to 10 million proteins due to alternative 
RNA splicing, overlapping of transcription units, post-translational processing and 
modifications[Lander et al., 2001; Venter et al., 2001]. Thus, a big disparity between genome 
and proteome exists, which indicates that the combinatorial diversification of regulatory 
networks lead to functional evolution of proteins. Through detecting the functioning units, 
proteomic studies generate a protein fingerprint, which reflects both the intrinsic genetic 
programme of the cell and the impact of its immediate environment.  Therefore, proteomics 
is valuable for biomarker discovery since its application provides higher opportunity to 
identify genuine determinants or causal factors involved in biological functions or the 
pathogenesis of disease.  
2.2 Two-dimensional electrophoresis-based proteomic findings of ESCC 
Two-dimensional electrophoresis (2DE) has been used for over 30 years now due to its high 
resolution for the separation of complex protein mixtures. In combination with mass 
spectrometry, 2DE has been so far the most commonly used method for analyzing protein 
expression and identity. Our laboratory used 2DE to profile the proteome from ESCC 
tumors and matched adjacent non-cancer mucosa, and proteome from immortalized 
esophageal cell line and cancer cell lines. Comparative analysis and MS for protein 
identification showed that the over-expressions of four proteins were common in ESCC 
tissues and cancer cell lines, which include tropomyosin isoform 4 (TPM4), prohibitin, 
peroxiredoxin (PRX1) and manganese superoxide dismutase (MnSOD); the expressions of 
another three proteins, i.e. stratifin, prohibitin, squamous cell carcinoma antigen 1 (SCCA1), 
were correlated inversely with dedifferentiation of ESCC[Qi et al., 2005; Qi et al., 2008]. 
Immunohistochemistry (IHC) analysis showed that loss of expressions of annexin A2 and 
stratifin were 45% and 64% in ESCC, respectively[Qi et al., 2007a; Qi et al., 2007b; Ren et al., 
2010]. Differential expressions of ten proteins including TPM1, SCCA1, stratifin, 
peroxiredoxin 2 isoform a, alpha B-crystalline, annexin A2, heterogeneous nuclear 
ribonucleoprotein L (hnRNP L), triosephosphate isomerase1 (TPI), laminA/C, and 
cyclophilin A (CypA) can be observed as well. Our findings may suggest that these 
differential proteins contribute to the multistage process of carcinogenesis, tumor 
progression, and invasiveness of ESCC. Published in the same issue, Zhou et al found 28 
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proteins aberrantly expressed in ESCC cancer cells with at least three-fold difference 
between ESCC and normal epithelial cells[Zhou et al., 2005]. The overlap between these two 
studies was quite small. Only expression of SCCA1 was commonly down-expressed in 
ESCC, but transgelin showed increased expression in tumor in our study and decreased 
expression in Zhou’s study. The disparity of proteins identified between these two studies 
may be due to different sample source, different methods used by these two groups, such as 
laser capture microdissection vs. bulk tissues, 2D-DIGE vs. silver staining. Later, five groups 
reported proteomic signatures associated with ESCC using ESCC samples collected from 
different regions of China, including high risk areas for ESCC such as Linzhou, Xinjiang and 
low risk areas like Beijing and Guangdong, but only four reports displayed details of 
identified proteins. Interestingly, more overlap of the identified proteins came from Fu’s 
study and ours, both of which used ESCC samples from Linzhou, one of the highest areas 
for ESCC adjacent to Taihang Mountain[Fu et al., 2007]. The commonly identified proteins 
with the same change direction included alpha enolase, TPM, tubulin, prohibitin and PRX2. 
Although the prevalence of ESCC in Xinjiang is comparable to Linzhou, the protein 
signatures were unique to sample origin, indicative of more important roles of 
environmental, ethnic or hereditary factors in the carcinogenesis of ESCC[Liu et al., 2011]. It 
seems that hsp27 was a general molecular events involved in ESCC since four out of five 
studies observed down-expression in ESCC except ours. Only one among seven studies 
performed survival assay after identifying the candidate proteins by ESCC proteomic 
profiling. Du et al. reported that over-expression of calreticulin and GRP78 could predicate 
poor prognosis of ESCC[Du et al., 2007]. Although 2DE is indeed a very useful method for 
biomarker discovery, more examinations of the biological functions and the clinical 
relevance of biomarker candidates involved in ESCC are necessary to verify its clinical 
value.  
Two reports described the proteomic signatures of ESCC with samples from Japan. 
Nishimori et al. used the agarose IEF gel in the first dimension, which not only allows for 
large-scale quantitative comparisons of protein expression but also is able to resolve high 
molecular mass proteins larger than 150 kDa[Nishimori et al., 2006]. As a result, a different 
protein pattern was revealed, including a few protein candidates with MW > 70 kDa. 
Western blot and IHC verified the different expression of a 195 kDa protein, periplakin, 
between cancer and adjacent non-cancer tissues. Not only was the expression of periplakin 
significantly down-regulated in ESCC but also translocation of periplakin was observed, 
which localized at cell-cell boundaries in normal epithelium and dysplastic precursor 
lesions, and disappeared from cell boundaries and shifted to cell cytoplasm in early cancers. 
The other research group from Japan used unsupervised classification to analyze the 2D-
DIGE protein spots and procured the protein signatures most relevant to clinical parameters 
with progression of ESCC[Hatakeyama et al., 2006]. The authors developed the largest 
protein database relevant to ESCC, which identified 240 proteins with expression level 
associated with carcinogenesis, histological differentiation and the number of lymph node 
metastases. A significant overlapping was observed between the proteins identified in ESCC 
with other different types of tumor. In addition, Jazii et al did proteomic profiling using 
ESCC samples from Iran, another high incidence area for ESCC like northern China, and 
identified six over-expressed proteins and six under-expressed proteins associated with 
ESCC[Jazii et al., 2006]. However, the authors only used RT-PCR to verify the loss of ǃ-
tropomyosin in ESCC. The functions of identified proteins associated with the development 
and progression of ESCC include cytoskeletal/structural organization, transport, chaperon, 
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oxioreduction, proliferation, glycolysis, cell motility, transcription, signal transduction, 
suggesting multiple dysregulated pathways involved in ESCC. For better understanding the 
pathogenesis of ESCC and development of biomarkers, integrated and comprehensive 
studies on these protein candidates are needed.  
An alternative approach to identify novel tumor biomarkers is the assessment of immune 
response elicited by tumor antigen since the humoral immune response to cancer in humans 
has been evidenced by the identification of autoantibodies to a variety of intracellular and 
surface antigens in cancer patients with different types of tumors[Chen et al., 2007; Disis et 
al., 1997; Hong et al., 2004; Soussi, 2000]. In ESCC, a number of reports have documented the 
presence of autoantibodies in serum against various proteins, including p53, cytokeratins, 
myomegalin, TRIM21, peroxiredoxin VI proteins, Hsp70, and CDC25B[Bergqvist et al., 2001; 
Fujita et al., 2006; Fujita et al., 2008; Liu et al., 2008; Shimada et al., 2007; Shimada et al., 2005; 
Veale et al., 1988]. The proteomic-based approach to identify panels of tumor antigens and 
related autoantibodies was introduced by Brichory et al. in 2001, which identified anti-
annexin I and II antibodies in sera from patients with lung cancer[Brichory et al., 2001]. 
There have been four articles published by two research groups, which reported the 
existence of autoantibodies in sera of ESCC patients. The first report was published by Fujita 
et al from Japan, who used 2DE to resolve protein extracts from ESCC cell line TE-2 as 
tumor antigens and then probed the blot with sera of ESCC patients, healthy controls and 
patients with other cancers[Fujita et al., 2006]. One positive spot was identified as PRX VI by 
MALDI TOF/TOF MS. The frequency of autoantibody against PRX VI was 50% (15/30) in 
ESCC, only 6.6% (2/30) in health controls and 3.3% (1/30) in colon cancer. Two years later, 
the same research group discovered augmented concentration of Hsp70 autoantibody in the 
serum of ESCC patients, which was significantly higher in ESCC patients than gastric and 
colon cancer, healthy controls[Fujita et al., 2008]. On the other hand, Liu et al. used ESCC 
tissue protein extracts and autologous sera to search for autoantibodies in ESCC patients 
and identified autoantibody CDC25B[Liu et al., 2008]. Furthermore, CDC25B expression was 
significantly higher in ESCC tissues with positive autoantibody CDC25B and significantly 
correlated with tumor stage. The sensitivity and specificity of autoantibody CDC25B for 
ESCC detection was 56.7% and 91%, respectively[Dong et al., 2010]. The autoantibody-
driven research is indeed a promising approach for the identification of novel serum 
biomarkers present in ESCC and for the tumor antigen itself, which may aid the diagnosis of 
ESCC and development of more effective immunotherapies.   
Similar to other cancers, development of multiple drug resistance in ESCC is one of major 
causes of failure to chemotherapy treatment. Furthermore, recent studies have shown that 
there exists intrinsic sensitivity and resistance to chemotherapy and/or radiotherapy in 
malignant cells of ESCC, which may predict clinical outcome of ESCC patients receiving 
neoadjuvant chemotherapy. Prior stratification of ESCC patients according to reliable 
biomarkers could not only save patients unnecessary adverse effects of chemotherapeutic 
agents but also render patients more chance to access to alternative curative treatment 
options. Therefore, it is imperative to define new diagnostic indicators that can reliably 
predict response to chemotherapy and radiotherapy in advance. A recent study compared 
the 2DE gels of parental esophageal cancer cell line EC109 and its resistant sub-cell line 
EC109/CDDP to determine the different proteins spots and identified 44 proteins with 
potential contribution to chemotherapy resistance[Wen et al., 2010]. In another study, 
radioactive 2DE proteomic comparative analysis was performed using protein extracts of 
biopsies from 34 patients with locally advanced EAC receiving neoadjuvant chemotherapy. 
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The identified proteins with different expression between responders and non-responders 
were classified into two major families, cytoskeleton proteins and molecular chaperon 
proteins. Further validation by IHC and RT-PCR showed that weak expression of HSP27 at 
protein level and mRNA level were associated with non-response to platin-based 
chemotherapy[Langer et al., 2008]. As serum represents a rich source for biomarker 
discovery, proteomic spectra were examined using 27 and 12 serum samples of responders 
and non-responders, respectively, to preoperative chemoradiotherapy in a training set by 
surface-enhanced laser desorption and ionization coupled with mass spectrometry analysis. 
A proteomic classifier comprising four mass peaks, at 7 420, 9 112, 17 123 and 12 867 m/z 
was identified with 93.3% predicative accuracy in the validation set[Hayashida et al., 2005]. 
Since chemotherapy resistance is a complex and multi-factorial event, proteomic-based 
studies enable comprehensive characterization of resistance phenotype of malignant 
cancers, which may lead to identification of potential distinguishing biomarkers between 
responders and non-responders and lay foundation for further molecular mechanism 
studies.  
In addition of 2DE gel for proteomic studies, surface enhanced laser desorption/ionization 
time-of-flight mass spectrometry (SELDI-TOF-MS) is an alternative proteomic tool to profile 
the serum or other body fluids and define potential protein pattern with diagnostic 
potential. By profiling of the serum proteome with SELDI-TOF-MS combined with 
bioinformatics tools, a number of highly sensitive and specific potential diagnosis markers 
have been revealed in various types of cancers. Wang et al. used weak cation exchange 
(WCX2) protein chips and SELDI-TOF-MS to profile 130 symptom-free serum samples 
collected from high-incidence area of ESCC in northern China, Linzhou, which included 63 
subjects with normal esophageal mucosa, 40 subjects with basal cell hyperplasia, 27 subjects 
with dysplasia and 30 ESCC patients. Biomarker pattern’s software identified four protein 
features at m/z of 9 306.61, 13 765.9, 2 942.15 and 15 953.4, which could distinguish normal 
esophageal epithelium, basal cell hyperplasia, dysplasia and ESCC with satisfactory 
diagnostic accuracy[Wang et al., 2006]. Xinjiang is one of the high-incidence areas for ESCC 
and comprise different ethnic peoples including Han decent. Using CM10 protein chips to 
capture targets from serum, SELDI-TOF-MS and bioinformatics analysis resulted in 
identification of six protein peaks (m/z 5667, 5790, 5876, 5979, 6043 and 6102) with 
diagnostic power with sensitivity and specificity of 91.43% and 88.89%, respectively[Xu et 
al., 2009]. In the case of ESCC profiled by SELDI-TOF-MS, further purification and 
identification of discriminatory peaks is necessary for development of simple methods for 
wider clinical application, and to enhance our understanding of the molecular mechanisms 
of esophageal carcinogenesis as well.  
2.3 SILAC-based proteomic findings of ESCC 
Quantitative proteomics is one of the hot research fields in post-genomic era, which has 
been used extensively in oncology to identify biomarkers with diagnostic and therapeutic 
potential, thereby avoiding proteins without biological importance. In traditional 2DE, 
quantitative information of protein spots on 2DE gels is represented by staining intensity. 
Although 2DE is a versatile tool for visualization of thousands of proteins, detection of post-
translational modified isoforms and targeting of protein expression alternations, it has 
inherent limitations, such as limited resolution of membrane or extreme pI proteins, low 
sensitivity and throughput, poor reproducibility, etc., which result in only part of proteome 
uncovered[Ong & Mann, 2005]. In this context, two classes of MS-based quantitative  
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Protein name T/N ratio Functions References 
Annexin A2 ↑or ↓ 
Calcium-dependent 
phospholipid binding 
calcium ion binding 
[Du et al., 2007; Liu et al., 2011] 
Annexin A8 ↓ [Nishimori et al., 2006] 
Annexin I ↓or↑ 
[Du et al., 2007; Jazii et al., 2006; Liu 
et al., 2011; Nishimori et al., 2006; 
Zhou et al., 2005; Zhu et al., 2010] 
Annexin V ↑ [Du et al., 2007] 
Annexin VI ↓ [Nishimori et al., 2006] 
Reticulocalbin ↑ [Zhou et al., 2005] 
S100 A9 ↓ 
calcium ion binding 
[Zhou et al., 2005] 
Syntaxin binding protein ↑ [Liu et al., 2011] 
Translationally controlled tumor 
protein 
↑ [Zhu et al., 2010] 
Zinc finger protein 410 ↑ Zink/DNA binding [Du et al., 2007] 
Mutuant hemoglobin beta chain ↓ 
Heme binding 
[Du et al., 2007] 
Myoglobin ↓ [Zhu et al., 2010] 
TPM-4-ALK fusion oncoprotein type 2 ↑ NA [Du et al., 2007; Jazii et al., 2006] 
TPM ↓ 
Cytoskeleton constituent  
[Fu et al., 2007; Liu et al., 2011; 
Nishimori et al., 2006; Zhou et al., 
2005] 
TPM2 ↓ [Jazii et al., 2006; Nishimori et al., 
2006; Zhu et al., 2010] 
TPM1 ↓ [Qi et al., 2005] 
TPM3 ↑or ↓ [Fu et al., 2007; Zhu et al., 2010] 
TPM4 ↑ [Qi et al., 2005] 
TPM isoform  ↑ [Fu et al., 2007; Qi et al., 2005] 
Vinculin ↓ [Nishimori et al., 2006] 
Capping protein, gelsolin-like ↓ [Fu et al., 2007] 
Smooth muscle myosin heavy chain 11 
isoform SM1 
↓ [Nishimori et al., 2006] 
Smooth muscle protein ↓ [Liu et al., 2011] 
Apha-actinin 4 ↑ [Fu et al., 2007] 
Tubulin alpha-6, ubiquitous ↑ [Fu et al., 2007] 
Tubulin beta-5 chain ↑ [Fu et al., 2007; Qi et al., 2005] 
Gamma-actin ↑ [Qi et al., 2005] 
Beta-actin ↑ [Fu et al., 2007] 
ACTB protein ↑ [Liu et al., 2011] 
Profilin-1 ↑ [Zhu et al., 2010] 
Periplakin ↓ [Nishimori et al., 2006] 
Calreticulin ↑ Stress response and 
immunity 
[Du et al., 2007; Jazii et al., 2006] 
Calreticulin precursor ↑ [Nishimori et al., 2006] 
Keratin 6A ↑ Intermediate filament [Du et al., 2007] 
Keratin 1 ↑ 
Intermediate filament 
[Jazii et al., 2006; Zhou et al., 2005] 
Keratin 6 ↑ [Nishimori et al., 2006] 
Keratin 8 ↓ [Zhou et al., 2005] 
Keratin 13 ↓ [Nishimori et al., 2006; Zhou et al., 
2005] 
Desmin ↓ [Nishimori et al., 2006; Zhou et al., 
2005] 
Vimentin ↑ [Nishimori et al., 2006] 
MnSOD ↑ Superoxide dismutase 
activity 
[Du et al., 2007; Qi et al., 2005] 
Proliferation cell nuclear antigen 
(PCNA) 
↑ DNA polymerase activity [Du et al., 2007; Zhou et al., 2005] 
PRO1708 ↑ 
Stress response and 
chaperone binding 
[Du et al., 2007] 
Dank-type molecular chaperone 
HSPAIL 
↑ or ↓ [Du et al., 2007; Nishimori et al., 2006] 
DnaJ(Hsp40) homolog ↑ [Nishimori et al., 2006] 
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Heat shock protein 27 kDa ↓ or ↑ [Du et al., 2007; Fu et al., 2007; Liu et 
al., 2011; Zhou et al., 2005] 
Similar to heat shock congnate 71-kDa 
protein 
↑ [Du et al., 2007] 
Heat shock 70kDa protein 8 ↓ [Nishimori et al., 2006] 
Heat shock protein 70 kDa ↑ [Jazii et al., 2006] 
gp96 ↑ [Zhou et al., 2005] 
GRP78 ↑ [Du et al., 2007] 
Alpha-B-Crystalline ↓ [Qi et al., 2005; Zhu et al., 2010] 
Fibrin beta ↓ [Liu et al., 2011] 
Crystal structure of huma recombinant 
procathepsin B 
↑ NA [Du et al., 2007] 
M2-type pyruvate kinase ↑or ↑ 
Energy metabolism 
[Du et al., 2007; Fu et al., 2007; Liu et 
al., 2011] 
Mutant beta-actin(Q6F5I1) ↑ [Du et al., 2007] 
Phosphoglycerate kinase 1 ↑ [Du et al., 2007; Nishimori et al., 2006] 
Alpha enolase ↑ [Du et al., 2007; Fu et al., 2007; 
Nishimori et al., 2006; Qi et al., 2005] 
Beat-enolase ↑ [Fu et al., 2007] 
Triosephosphate isomerase ↑ [Zhu et al., 2010] 
GAPDH ↑ [Qi et al., 2005] 
Aldolase A ↓ [Nishimori et al., 2006] 
Fructose-bisphosphate aldolase A ↓ [Zhu et al., 2010] 
RNA binding motif protein 8A ↑ mRNA/nucleotide/protei
n binding 
[Zhou et al., 2005] 
Translation initiation factor Eif-1A ↑ Translation [Zhou et al., 2005] 
Transmembrane protein 4 ↑ 
Protein binding 
[Zhou et al., 2005] 
Transgelin ↓or ↑ [Liu et al., 2011; Qi et al., 2005; Zhou 
et al., 2005; Zhu et al., 2010] 
COMT protein ↑ [Liu et al., 2011] 
Early endosome antigen 1 ↓ 
Protein binding 
[Liu et al., 2011] 
Crystal structure of recombinant human 
fibrinogen fragment 
↑ [Nishimori et al., 2006] 
Similar to ubiquitin -conjugating 
enzyme E2 variant 1 isoform 
↓ 
Protein degradation 
[Du et al., 2007] 
Ubiquitin C-terminal esterase ↑ [Zhou et al., 2005] 
Ubiquinol-cytochrome C reductase 
complex core protein2 
↑ [Nishimori et al., 2006] 
Proteosome ↑ [Liu et al., 2011] 
Galectin-7 ↓ Interactionof cells and 
cell-matrix  
[Zhou et al., 2005; Zhu et al., 2010] 
Fatty acid-binding protein ↓ Lipid metabolism [Zhou et al., 2005] 
TGase  ↓ Protein modification [Zhou et al., 2005] 
Fascin  ↑ actin cross-lining [Zhou et al., 2005] 
SCCA1 ↓ Cysteine proteinase 
inhibitor 
[Qi et al., 2005; Zhou et al., 2005] 
Proteinase inhibitor, Clade B ↓ Neutrophil elastase 
inhibitor 
[Zhou et al., 2005] 
Thioredoxin perosidase ↑ 
Redox homeostasis 
[Zhou et al., 2005; Zhu et al., 2010] 
Peroxiredoxin 1 ↑or ↓ [Fu et al., 2007; Qi et al., 2005] 
Peroxiredoxin 2 ↓ [Jazii et al., 2006; Qi et al., 2005] 
ARK family 1 ↑ Carcinogen metabolism [Zhou et al., 2005] 
GST M2 ↑ glutathione transferase 
activity 
[Zhou et al., 2005] 
Proteasome subunit ǃtype 4 ↑ 
Protein degradation 
[Zhou et al., 2005] 
Proteasome subunit ǃtype 9 ↓ [Zhou et al., 2005] 
Prosomal protein p30-33k ↑ [Zhou et al., 2005] 
Elongation factor Tu ↑ Translation [Qi et al., 2005] 
(NADP) cytoplasmic  ↑ NAD binding [Qi et al., 2005] 
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Prohibitin ↑or ↓ Transcription regulation [Fu et al., 2007; Qi et al., 2005] 
Neuronal protein ↑ Neuronal growth [Qi et al., 2005] 
Nuclear autoantigenic sperm protein 
isoform 1 
↑ Hsp90 protein binding [Nishimori et al., 2006] 
Myosin heavy chain nonmuscle form A ↓ Actin binding or 
calmodulin binding 
[Nishimori et al., 2006] 
Caldesmon 1 isoform 1 ↓ [Nishimori et al., 2006] 
Myosin regulatory light chain 2 ↓ Ventricular/cardiac 
muscle isoform 
[Jazii et al., 2006; Zhu et al., 2010] 
Myosin light chain 2 ↓ Regulatory light chain of 
myosin 
[Jazii et al., 2006] 
Myosin light chain 1 ↓ [Zhu et al., 2010] 
Heterogeneous nuclear 
ribonucleoprotein A2/B1:B1 
↑ 
RNA binding and 
processing 
[Nishimori et al., 2006] 
Heterogeneous nuclear 
ribonucleoprotein A2/B1:A2 
↑ [Nishimori et al., 2006] 
Myosin light chain 3 ↓ 
Regulatory light chain 
[Zhu et al., 2010] 
Myosin light polypeptide 6 ↑ [Jazii et al., 2006] 
Myosin light chain 6B ↓ Regulatory light chain [Zhu et al., 2010] 
Similar to alpha-fetoprotein ↓ NA [Nishimori et al., 2006] 
Trnasferrin ↓ ferric iron binding [Nishimori et al., 2006] 
Alpha-1-antitrypsin precursor ↓ 
Proteinase inhibitor 
[Nishimori et al., 2006] 
Alpha-1-antitrypsin ↑ [Fu et al., 2007] 
Procollagen-proline ↓ Oxidoreductase activity [Nishimori et al., 2006] 
Calponin 1, basic ↓ actin binding ; 
calmodulin binding 
[Nishimori et al., 2006] 
DNA directed RNA polymerase B 
(ropB) 
↑ Transcription [Jazii et al., 2006] 
GH16431P ↑ NA [Jazii et al., 2006] 
OPTN protein ↓ Protein C-terminus 
binding 
[Fu et al., 2007] 
67 kDa laminin receptor ↑ 
Signal transduction 
[Fu et al., 2007] 
TNF receptor associated factor 7 ↑ [Liu et al., 2011] 
Stratifin ↓ [Du et al., 2007; Qi et al., 2005] 
Cathepsin D ↑ Aspartyl proteinase 
activity 
[Liu et al., 2011] 
Chromosome1 open reading frame 8 ↑ NA [Liu et al., 2011] 
Cdc42 ↑ GTPase activator activity [Liu et al., 2011] 
LLDBP ↑ NA [Liu et al., 2011] 
Adenylate kinase 1 ↓ Adenylate kinase activity [Liu et al., 2011] 
General transcription factor IIH ↓ Transcription [Liu et al., 2011] 
Serpin B5 precursor ↑ 
serine proteinase inhibitor
[Zhu et al., 2010] 
Serpin B3 ↑ [Zhu et al., 2010] 
Transthyretin [Precursor] ↑ Thyroid hormone-binding 
protein 
[Zhu et al., 2010] 
Apolipoprotein A-I [Precursor] ↑ lipid metabolism [Zhu et al., 2010] 
Peptidyl-prolyl cis-trans isomerase A ↑ Peptidyl-prolyl cis-trans 
isomerase activity 
[Zhu et al., 2010] 
Cystatin-B ↑ 
Cysteine-type 
endopeptidase inhibitor 
activity 
[Zhu et al., 2010] 
Serum amyloid P-component 
[Precursor] 
↓ Protein binding [Zhu et al., 2010] 
Phosphatidylethanolamine-binding 
protein1 
↓ Serine-type 
endopeptidase inhibitor 
[Zhu et al., 2010] 
Carbonic anhydrase 1 ↓ Carbonate dehydratase 
activity 
[Zhu et al., 2010] 
Carbonic anhydrase 3 ↓ [Zhu et al., 2010] 
Creatine kinase M-type ↓ Creatine kinase activity [Zhu et al., 2010] 
Table 1. Reported differential proteins in esophageal cancer tissues 
www.intechopen.com
 
Proteomics – Human Diseases and Protein Functions 
 
266 
proteomics methods have been developed, which include extracted ion current (XIC)-based 
label-free quantification and stable isotope labeling quantification. Stable isotope labeling by 
amino acids in cell culture (SILAC) is an in vivo metabolic labeling method in which stable 
isotope-labeled amino acids (Heavy vs. Light amino acids) replace the natural amino acids 
of preexisting proteome[Ong & Mann, 2006]. We used SILAC medium to label immortalized 
cells (NE3 and NE6) with heavy stable isotope [U-13C6]-H-Lysine and [U-13C6]-H-Arginine 
and cancer cells (EC1, EC109, EC9706) with light stable isotope [12C6]-L-Lysine and [12C6]-L-
Arginine, respectively. After complete labeling of the cellular proteome, equal quantity of 
proteins from immortalized cells and cancer cells were mixed and then subjected to SDS-
PAGE separation, in-gel trypsin digestion and high performance liquid chromatography on-
line with electrospray ionization-MS/MS analysis (HPLC-ESI-MS/MS). Forty-seven 
candidate proteins with differential expression were identified with our arbitrary criteria, 
which contains ratio change > 1.5 folds, ≥ 2 peptides for quantification and coefficient of 
variation < 50%. Then, we characterized the cellular protein expression pattern and 
secretome derived from cisplatin-resistant sub-cell line EC9706 and its parental sensitive cell 
line EC9706. By SILAC labeling and MS-based quantification, we successfully identified 74 
proteins of cellular origin and 57 proteins of secretome with altered expression levels. 
Similar to our approach, Kashyap et al. used a SILAC-based quantitative proteomic 
approach to compare the secretome of ESCC cells with that of non-neoplastic esophageal 
squamous epithelial cells and identified 120 up-regulated proteins with >2-fold difference in 
the ESCC secretome[Kashyap et al., 2010]. In addition of previously known increased ESCC 
biomarkers, i.e. matrix metalloproteinase 1, transferrin receptor, and transforming growth 
factor beta-induced 68 kDa, a number of novel proteins showed distinct expression pattern, 
among which protein disulfide isomerase family a member 3 (PDIA3), GDP dissociation 
inhibitor 2 (GDI2), and lectin galactoside binding soluble 3 binding protein (LGALS3BP) 
were further validated by immunoblot analysis and immunohistochemical labeling using 
tissue microarrays. These identified proteins participate in multiple biological functions, 
including molecular chaperones, cytoskeletal proteins, and members of protein inhibitors 
family, reducing protein, etc., suggesting multiple dysregulated pathways involving in 
ESCC.  
2.4 Clinical relevance of potential protein biomarkers in ESCC 
To answer clinical questions, the protein biomarkers identified by proteomic techniques 
with potential diagnosis and therapeutic targets for ESCC need to be translated into clinical 
scenario, which is realized by using clinical samples, such as biopsy samples, resected tissue 
samples, plasma or serum samples, urine samples, saliva samples, etc. The methods used for 
validation generally comprise Western blot, IHC and ELISA at protein level, and RT-PCR at 
transcription level. Using 2DE- and SILAC-based quantitative proteomic approaches, we 
have identified a total of 78 non-redundant proteins with aberrant expression associated 
with ESCC, suggesting that these proteins may play functional roles in carcinogenesis of 
ESCC and may have clinical values. Afterwards, Western blot analysis verified the 
decreased expressions of three proteins, i.e. SCCA1, TPM1 and ǂB-Cryst in cancer, in 
accordance with 2DE quantitative results. At transcription level, SCCA1 mRNA was down-
regulated in tumor as well. More importantly, the expression of SCCA1 decreased step by 
step as a function of precancer lesions progression, which suggests that SCCA1 may take 
part in the multi-stage transformation of ESCC, even in the earliest stages[Qi et al., 2005]. In 
the 2DE-based comparative proteomic study using immortalized and cancer cell model, we  
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Accession no. Protein name MW/PI Scores
Ratio
(T/N)
Matched 
peptides 
Functions 
TPM3 HUMAN Tropomyosin alpha-3 chain 32.80/4.53 330.06 0.47 2 
Actin binding 
TPM4 HUMAN Tropomyosin alpha-4 chain 28.50/4.52 199.64 0.37 2 
K2C8  HUMAN Keratin, type II cytoskeletal 8 53.67/5.38 907.48 0.51 4 
 
FSCN1  HUMAN Fascin 54.50/7.02 296.56 0.45 2 
LEG1  HUMAN Galectin-1 14.71/5.18 424.98 0.49 3 
Signal 
transduction 
CLIC1  HUMAN Chloride channel ABP 26.91/4.94 447.94 0.63 4 
1433E  HUMAN 14-3-3 protein epsilon 29.16/4.48 400.71 0.66 3 
PRDX1  HUMAN Peroxiredoxin-1 22.10/9.22 689.77 0.55 7 
Redox 
homeostasis 
PRDX2  HUMAN Peroxiredoxin-2 21.88/5.59 238.11 0.65 5 
PRDX4  HUMAN Peroxiredoxin-4 30.52/5.85 367.60 0.34 2 
PRDX5  HUMAN Peroxiredoxin-5 22.01/9.93 522.84 0.60 2 
CBR1  HUMAN 
Carbonyl reductase 
[NADPH]1 
30.36/9.53 467.30 0.59 2 
KCRB  HUMAN Creatine kinase B-type 42.62/5.25 711.33 1.67 4 
Metabolic 
process 
GSTP1  HUMAN Glutathione S-transferase P 23.34/5.32 1140.8 0.45 6 
GDIB  HUMAN Rab GDI beat 50.63/6.08 614.67 0.47 2 
DHSA  HUMAN 
Favoprotein subunit 
complex II 
72.65/7.31 207.55 0.5 2 
ACBP  HUMAN Acyl-CoA-binding protein 10.04/6.16 135.03 0.64 2 
PHS  HUMAN PHS 2 11.99/6.33 170.64 0.43 3 
RL27A  HUMAN 60S ribosomal protein L27a 
16.55/11.7
8 
233.25 0.59 2 
Translation 
RSSA  HUMAN 40S ribosomal protein SA 32.83/4.64 298.67 0.58 2 
IF4G1_HUMAN eIF-4-gamma 1 175.4/5.1 650.5 2.15 14 
NPM  HUMAN Nucleophosmin 32.55/4.49 444.46 0.52 2 DNA binding 
GRP78  HUMAN GRP78 72.29/4.92
1869.0
9 
0.50 14 Chaperone 
binding 
CH10  HUMAN Hsp 10 10.92/9.44 219.29 0.40 3 
G6PI  HUMAN 
Glucose-6-phosphate 
isomerase 
63.11/9.10 510.30 0.48 5 
Energy 
metabolism 
UGDH  HUMAN 
UDP-glucose 6-
dehydrogenase 
54.99/6.89 604.20 0.53 2 
PPIA  HUMAN Peptidyl-prolyl isomerase A 18.00/9.05 770.25 0.59 9 
ALDOA HUMAN
Fructose-bisphosphate 
aldolase A 
39.40/9.18 386.91 0.59 2 
PGK1  HUMAN Phosphoglycerate kinase 1 44.59/9.22 1020.8 0.50 6 
G3P  HUMAN GAPDH 36.03/9.26 1127.9 0.52 8 
IPYR  HUMAN Inorganic pyrophosphatase 32.64/5.47 485.51 0.45 3 
ENOA  HUMAN Alpha-enolase 47.14/7.71 1998.1 0.55 15 
CYTB  HUMAN Cystatin-B 11.13/7.85 144.98 0.43 2 
CPSM  HUMAN 
Carbamoyl-phosphate 
synthase 1 
164.83/6.3
0 
3115.1 0.24 6 
PHB2  HUMAN Prohibitin-2 
33.28/10.2
1 
546.79 0.47 2 
Transcription 
regulation 
CAND1_HUMAN
TBP-interacting protein 
120A 
136.3/5.4 617.2 1.8 15 
PSME2 HUMAN 
Proteasome activator 
complex subunit2 
27.34/5.33 367.19 0.48 2 
Cell cycle 
MCM7_HUMAN 
DNA replication licensing 
factor MCM7 
81.3/6.1 510.8 1.97 13 
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Accession no. Protein name MW/PI Scores
Ratio
(T/N)
Matched 
peptides 
Functions 
ACADV HUMAN VLCAD 70.35/9.63 841.39 0.35 2 
Lipid 
metabolism 
ATPA  HUMAN ATP5A1 59.71/9.61 963.07 0.47 5 
THIL  HUMAN Acetoacetyl-CoA thiolase 45.17/9.63 330.39 0.45 2 
MIF  HUMAN 
Macrophage migration 
inhibitory factor 
12.47/9.12 267.01 0.61 3 
Cytokine 
activity 
ATPB  HUMAN ATPB-3 56.52/5.14 1704.2 0.40 5 Ion transport 
VDAC1 HUMAN VDAC-1 30.75/9.22 548.36 2.32 2 
Anion 
transport 
VPS35_HUMAN hVPS35 91.6/5.2 602.6 1.67 12 
Protein 
transport 
HYOU1 HUMAN
Hypoxia up-regulated 
protein 1 
111.27/5.0
2 
1206.8 0.56 2 ATP binding 
SMD3  HUMAN 
Small nuclear 
ribonucleoprotein 3 
13.91/11.0
7 
330.93 0.49 2 
mRNA 
processing 
Table 2. Differential proteins between immortalized and cancer cell lines derived from ESCC 
identified by SILAC-based proteomics 
selected Annexin A2 for validation by Western blot and IHC. Stepwise decrease in annexin 
A2 protein expression was observed when epithelial cell was transformed malignantly. In 
poorly-differentiated squamous carcinoma, 46% (5/11) of cancer tissue sample lost annexin 
A2 protein and 36% (4/11) expressed at weak intensity[Qi et al., 2007b]. In a separate study, 
IHC was used to determine 14-3-3σ in 60 cases of ESCC, nearby matched normal esophageal 
epithelium and a variety of ESCC precursor lesions. High level of 14-3-3σ expression was 
found ubiquitously in normal esophageal epithelium with an immuonstaining score of 8.22 
in expression. Protein 14-3-3σ was down-regulated stepwise during the multi-stage 
development of ESCC. Sixty-four percent of poorly-differentiated squamous cancer lost 14-
3-3σ expression with a score of 0.45[Qi et al., 2007a]. In agreement with our results, Ren et al. 
documented that the level of 14-3-3σ in terms of mRNA and protein was markedly down-
regulated in ESCC compared with nearby matched non-cancer tissues. Furthermore, 
decrease of 14-3-3σ expression was correlated with tumor infiltration depth, lymph node 
metastasis, distant metastasis and lymphovascular invasion and shorter 5-year survival 
rate[Ren et al., 2010]. Among the different proteins identified by SILAC-based quantitative 
analysis using immortal cell and cancer cell model, the clinical values of MIF in 
tumorigenesis of ESCC was determined as well. Not only the increased expression of MIF 
was detected in cellular protein but also in the conditioned medium of esophageal cancer 
cell lines EC1, EC109 and EC9706 compared with immortal cell lines NE3 and NE6. Low 
frequency and very weak expression of MIF was detected predominantly in basal cells in 
normal esophageal epithelium, with an immunostaining score of 1.13. Pronouncedly up-
regulated expression of MIF occurred in severe dysplasia compared with weak 
immunostaining in mild and moderate dysplasia. In ESCC, high frequency of intense 
expression of MIF was observed with a score of 5.46. Furthermore, high expression of MIF 
was significantly correlated with advanced clinical stages. ELISA tests revealed that there 
was an increase trend in serum level of MIF in clinically advanced stage IV compared to 
stage I-III. Functional studies on MIF indicated that MIF knockdown resulted in decrease in 
proliferation, clonogenicity, non-adherent growth and invasive potential. Our findings 
indicate that MIF may play crucial roles in malignant transformation of pathogenesis of EC 
and MIF could become a potential biomarker for high-risk population screening, assessment 
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of therapeutic efficiency, prognostic evaluation, and molecular targets of developing novel 
therapeutic regimen as well. In addition of our proteomic results in ESCC, several other 
reports have looked at the clinical value of potential biomarkers, including cytokeratin 14, 
Annexin I, SCCA1/2, calgulanulin B and HSP 60, alpha-actinin 4 and 67 kDa laminin 
receptor, cathepsin D and PKM2, periplakin, calreticulin and GRP78, galectin-7, anti-CD25B 
antibody[Dong et al., 2010; Du et al., 2007; Fu et al., 2007; Hatakeyama et al., 2006; Liu et al., 
2011; Nishimori et al., 2006; Zhu et al., 2010]. Nevertheless, further extensive studies are still 
necessary to determine the clinical utility of the identified proteins in tumorigenesis and 
progression of ESCC. 
3. Conclusions 
Nowadays, the dilemma for cancer control and management is not due to lack of efficient 
treatment options but diagnosis at late stages. In the case of ESCC in China, five-year 
survival rate for early stage tumor reaches around 90%[Hu et al., 2001]. Obviously, to detect 
tumor as early as possible is the key for reducing the mortality and morbidity of ESCC. It is 
believed that development of ESCC from normal esophageal epithelium takes at least about 
10 years, during which diseased epithelium manifests as basal cell hyperproliferation, 
dysplasia, carcinoma in situ in terms of morphology and finally evolves to malignant 
neoplasms. As such, carcinogenesis of ESCC is a multi-stage and dynamic process which 
accumulates ongoing changes at the level of both gene and protein expression.  
Proteomic studies from various research groups worldwide have identified distinct 
dysregulated protein expression pattern associated with ESCC. The discrepancy might 
reflect the different etiology, different stages of disease and diverse pathways involved, 
which makes identification of biomarkers for ESCC difficult. In light of a wealth of potential 
biomarkers associated with ESCC identified so far in the exploratory phase, future large-
scale validation studies involving symptom-free patients with precursor lesions in high-
incidence area and ESCC patients compared with controls are essential toward clinical 
application. Therefore, ultimate translation from laboratory into bedside for ESCC 
biomarkers will require close collaboration and cooperation between researchers and 
clinicians to look into the clinical utility in diagnosis at early stage, prognosis and 
monitoring treatment efficiency for ESCC. 
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